INTRODUCTORY NOTE
Pursuant to Rule 13d-2 under the U.S. Securities Exchange Act of 1934, as amended (the Act), this Amendment No. 3 (the
Amendment) amends and supplements certain items of the Schedule 13D for the common shares, no par value (the Common Shares) of Arbutus Biopharma Corporation (the Issuer), filed with the U.S. Securities and
Exchange Commission (the SEC) on September 15, 2017, as amended by Amendment No. 1 to the Schedule 13D filed with the SEC on October 17, 2017, and Amendment No. 2 to the Schedule 13D filed with the SEC on
January 16, 2018 (as so amended, the Original Schedule 13D). This Amendment is filed by SVF Investments (UK) Limited, a limited company organized under the laws of England and Wales (SVF Investments), which is a wholly
owned subsidiary of SVF Holdings (UK) LLP, a limited liability partnership organized under the laws of England and Wales (SVF Holdings), which is a wholly owned subsidiary of SoftBank Vision Fund L.P., a limited partnership organized
under the laws of Jersey (SoftBank Vision Fund). This Amendment is also filed by SVF GP (Jersey) Limited, a limited company organized under the laws of Jersey and the general partner of Softbank Vision Fund (SVF GP and,
together with the SVF Investments, SVF Holdings and SoftBank Vision Fund, the Reporting Persons).
This Amendment constitutes an exit filing
for the Reporting Persons. Due to changes in the internal governance of Roivant Sciences Ltd. (Roivant) relating to Roivants dispositive power over the Common Shares, the Reporting Persons are no longer deemed to beneficially own
the Common Shares directly owned by Roivant. Additionally, based on other changes in Roivants internal governance relating to oversight of Roivants business and governance, the Reporting Persons are no longer deemed to control Roivant
within the meaning of Instruction C to Schedule 13D. Roivants ownership of the Issuers Common Shares remains unchanged and this filing is not being made as a result of the purchase or sale of Common Shares of the Issuer by any party,
including the Reporting Persons. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.
Item 2. Identity and Background.
Item 2 of the
Schedule 13D is hereby amended and restated as follows:
(a) (c)
|
SoftBank Covered Persons
|
SVF Investments is a wholly owned subsidiary of SVF Holdings. SoftBank Vision Fund is the managing member of SVF Holdings. SVF GP is the
general partner of Softbank Vision Fund. As such, each of SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP may be deemed to share beneficial ownership of the Common Shares directly owned by Roivant.
The principal executive offices of SVF Investments and SVF Holdings is 69 Grosvenor Street, London, United Kingdom W1K 3JP. The principal
executive office of SVF GP and Softbank Vision Fund is Aztec Group House, 11-15 Seaton Place, St. Helier, Jersey JE4 0QH.
The principal
business of SVF GP is the management and control of the business of the SoftBank Vision Fund. The principal business of the SoftBank Vision Fund is to engage in making investments in securities of public and private companies. The principal business
of SVF Investments and SVF Holdings is to directly hold securities of public and private companies, as determined by SVF GP, via SoftBank Vision Fund.
Each of Adam Nicholas Gulley, Rajeev Misra, Simon King and Robert David Milner is a managing director of SVF GP. Their principal business
addresses, present principal occupations and countries of citizenship are set forth below. SVF Investments, SVF Holdings, SoftBank Vision Fund, SVF GP and such managing directors of SVF GP are referred to herein as the
SoftBank Covered
Persons
.
|
|
|
|
|
|
|
Name
|
|
Principal Business Address
|
|
Present Principal
Occupation
|
|
Citizenship
|
Adam Nicholas Gulley
|
|
69 Grosvenor Street, London, United Kingdom W1K 3JP
|
|
Director
|
|
United Kingdom
|
Rajeev Misra
|
|
69 Grosvenor Street, London, United Kingdom W1K 3JP
|
|
Director
|
|
United Kingdom
|
Simon King
|
|
Aztec Group House
11-15 Seaton Place,
St. Helier, Jersey JE4 0QH
|
|
Director
|
|
United Kingdom
|
Robert David Milner
|
|
Aztec Group House
11-15 Seaton Place,
St. Helier, Jersey JE4 0QH
|
|
Director and Attorney
|
|
United Kingdom
|
Page 6 of 8